Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06798727
PHASE2

Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control

Sponsor: Medipost Co Ltd.

View on ClinicalTrials.gov

Summary

This is a follow-up study to investigate the long-term safety and explore efficacy of SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and completed the initial stage of the Phase II trial (NCT05182034) will be followed-up until 60 months.

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

84

Start Date

2023-03-20

Completion Date

2027-11-30

Last Updated

2025-02-07

Healthy Volunteers

No

Interventions

BIOLOGICAL

SMUP-IA-01(low-dose)

A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

BIOLOGICAL

SMUP-IA-01(mid-dose)

A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

DRUG

High Hyal Plus

A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)

Locations (5)

Seoul Nation University Bundang Hospital

Gyeonggi-do, South Korea

Gangnam Severance Hospital

Seoul, South Korea

Korea University Anam Hospita

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Severance Hospital

Seoul, South Korea